An analysis of the large global DELIVER trial found that dapagliflozin improved outcomes and symptoms across a wide range of patients with heart failure.
People with type 2 diabetes who tried agents from three different classes of glucose-lowering drugs usually found one they liked most. It was also often their safest and most effective option.
SGLT2 inhibitors, publishing choices, second and third order effects of interventions, decision support, and patient selection for preventive procedures are the topics John Mandrola, MD, discusses in this week’s podcast.
Empagliflozin s efficacy in a range of patients with chronic kidney disease in EMPA-Kidney filled evidence gaps and confirmed SGLT2 inhibitors as a key treatment regardless of diabetes status.
Thailand: A recent study published in Cardiovascular Diabetology has compared the treatment effectiveness of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on renal outcomes with other second-line.